# CLARINET FORTE (NCT02651987)

> Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02651987
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Ipsen
- Conditions: Pancreatic Tumours; Midgut Neuroendocrine Tumours
- Interventions: Lanreotide autogel 120 mg
- Enrollment: 99
- Primary outcome: Median Progression Free Survival (PFS)

## Commentary we found

- YouTube: 8
- Podcasts: 5
- X threads: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=clarinet-forte-nct02651987

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02651987", "email": "<work email>"}; the inbox owner confirms by the emailed link.